Generics and Pharmaceuticals

///Generics and Pharmaceuticals

Pharmaceutical abuse sent more than 350,000 people to the ER in 2016

The misuse of prescription drugs and over-the-counter medications resulted in an estimated 358,000 trips to U.S. emergency departments in 2016 — and almost half of those cases involved young people ages 15 to 34, according to a new study based on a national public health surveillance system. The analysis, reported online March 6 in the

2019-03-18T10:58:33-05:00Tags: |

Injectable pharmaceutical aims to accelerate bone healing

WEST LAFAYETTE, Ind. – Every person in the U.S. will experience, on average, two broken bones in their lifetime. It is expected that more than 6.3 million bones will be broken in the U.S. this year, according to the National Institutes of Health. Average recovery time for a young, healthy adult with a broken arm is six to

2019-03-12T11:27:52-05:00Tags: |

Do price spikes on some generic drugs indicate problems in the market?

A new USC study reports that sudden price spikes for some generic drugs — such as the recently reported increases of a decades-old generic heart medication and an antibiotic — are becoming more common. The study from the USC Schaeffer Center for Health Policy & Economics, published in the October issue of Health Affairs, shows

2019-03-07T07:48:35-05:00Tags: |

Pharmacists can substitute branded drugs with generics

The Prime Minister's office has asked the Drug Technical Advisory Board (DTAB) to move amendments to the Drugs & Cosmetics Act, 1945 that will allow pharmacists to substitute doctor's prescription of branded drugs with generic medicines. Following suggestions, the Drug Controller General of India confirmed that in the initial phase, only the Jan Aushadhi Kendras

2019-03-07T07:40:41-05:00Tags: |

Towards a sustainable system of drug development

Drug development has become the exclusive activity of large pharmaceutical companies. However, the output of new drugs has been decreasing for the past decade and the prices of new drugs have risen steadily, leading to access problems for many patients. By analyzing the history of drug development and the pharmaceutical industry, we identified the main

2019-02-27T07:09:19-05:00Tags: |

Drugmakers begin 2019 with price hikes

Americans woke up Tuesday to higher pharmacy costs as more than three dozen pharmaceutical companies raised their prices on hundreds of drugs including generic medicines, according to a study first reported by The Wall Street Journal. The health software company Rx Savings Solutions found that dozens of drugs produced by major brands such as Allergan and Hikma Pharmaceuticals saw

The Little-Known Way Pharma Companies Hook People On Their Costly Drugs

Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Amgen couldn’t cover the drug’s more than $4,000 monthly price. “Nothing in the world gives me

2018-12-13T07:48:27-05:00Tags: |

Epicenter of fake pharma

One consequence of African poverty is that quality medication is often unavailable. Health-care systems tend to be weak, and the marketing of pharmaceuticals is not regulated effectively. Many patients depend on sub-standard or even counterfeit drugs. In this setting, a powerful opioid has become easily available – addiction is spreading in West Africa. Tramadol is

2018-12-13T07:41:21-05:00Tags: |

Investigation of generic ‘cartel’ expands to 300 drugs

Executives at more than a dozen generic-drug companies had a form of shorthand to describe how they conducted business, insider lingo worked out over steak dinners, cocktail receptions and rounds of golf. The “sandbox,” according to investigators, was the market for generic prescription drugs, where everyone was expected to play nice. “Fair share” described dividing

Assessing the environmental risk of pharmaceuticals

AstraZeneca’s Jason Snape, outlined his company’s approach to the environmental risk assessment of human medicinal products and what more needs to be in place to accomplish sustainable healthcare. In October, Heath Europa attended CleanMed Europe 2018 at Radboud University Medical Center, Nijmegen, the Netherlands. This event, which explores sustainable healthcare, is designed to address the

2018-11-13T10:37:53-05:00Tags: |

Drug Companies, Not ‘Middlemen’, Are Responsible For High Drug Prices

As pharmaceutical companies have faced more heat for their pricing practices, they’ve found someone else to blame: “middlemen” who extract discounts from drugmakers. But in fact, if it weren’t for middlemen like wholesalers and pharmacy benefit managers, drug prices would be even higher. When Donald Trump was running for President in 2016, he promised to

Prescription for Poverty

Drug companies as tax dodgers, price gougers, and influence peddlers New Oxfam research shows that four pharmaceutical corporations—Abbott, Johnson & Johnson, Merck & CO (MSD), and Pfizer—systematically stash their profits in overseas tax havens. They appear to deprive developing countries of more than $100 million every year—money that is urgently needed to meet the health

2018-10-17T09:16:32-05:00Tags: |

Everyone Wants Pharmaceutical Breakthroughs. What Drives Drug Companies to Pursue Them?

When choosing which new products to develop, companies must decide how much they want to innovate. Should they make an incremental improvement on an existing product? Or should they create something entirely new? Dimitris Papanikolaou, a professor of finance at Kellogg, explored how this choice plays out in the pharmaceutical industry. Some researchers argue that

2018-09-13T08:01:19-05:00

The New Nonprofit Pharmaceutical World: What’s Up with That?

Two new nonprofit pharmaceutical companies, Civica Rx and Harm Reduction Therapeutics, have declared they want to help patients see more money in their pockets by manufacturing low-cost generic drugs. With public trust in for-profit pharmas at an all-time low, especially when it comes to their relationships with a special brand of self-serving philanthropy, they’d better

2018-09-13T07:49:36-05:00Tags: |

Hospitals Prepare To Launch Their Own Drug Company To Fight High Prices And Shortages

Sometimes IV bags are hard for hospitals to come by. Other times it's injectable folic acid to treat anemias. Right now, the tissue-numbing agent lidocaine is in short supply. Shortages of commonplace generic drugs have plagued hospitals in recent years. And with short supplies and fewer suppliers for key drugs, there have been price increases. Hospital purchasing agents keep

8,000 new antibiotic combinations are surprisingly effective

Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns. The prevailing theory is that that the incremental benefits of combining three or more drugs would be too small to matter, or that the interactions among the drugs would cause their benefits to cancel one another out.

2018-09-05T07:15:22-05:00Tags: |

Working group may vet plan to check fake drugs

NEW DELHI: India’s central drug regulator is creating a working group to critically appraise its proposal to set up a “trace and track” mechanism to weed out fake medicines from the market using unique codes. The working group, comprising pharmaceutical association representatives and members of the Central Drugs Standard Control Organisation, is to submit its

2018-08-21T08:28:29-05:00Tags: |

FDA Approves Teva’s Generic Version of Mylan’s EpiPen

Israel’s Teva Pharmaceuticals shares rallied after the U.S. Food and Drug Administration approved Thursday the company’s generic version of the best-selling, lifesaving allergy injection EpiPen. Although Teva didn’t say when it would begin sales of its product or its price, the approval promises to turn the company into a champion for the millions of Americans who use

It’s Generics Not PBMs That Keep Pharmaceuticals Affordable

Expenditures on prescription drugs grew 12.4 percent in 2014 and 8.9 percent in 2015. These eye-popping data are not representative of the long-term expenditure trend, however. Not only did the growth in prescription drugs expenditures slow to 1.3 percent in 2016, longer-term (between 2009 and 2016), the average annual growth in pharmaceutical expenditures was 3.8